Lifecore Biomedical Aktie
WKN: 899376 / ISIN: US5147661046
18.06.2025 05:40:02
|
Lifecore Signs 10-Year Manufacturing Deal To Support Novel Ophthalmic Therapy
(RTTNews) - Lifecore Biomedical, Inc. (LFCR) has entered a 10-year commercial manufacturing and supply agreement with an existing partner to advance a new ophthalmic treatment through clinical stages to market readiness.
The deal reflects Lifecore's broader growth strategy focused on late-stage customer projects approaching commercialization.
CEO Paul Josephs emphasized that this long-term agreement marks a key milestone in transitioning from development to revenue-generating commercial manufacturing. In parallel, Lifecore signed a multi-million-dollar statement of work to deliver a series of fill and finish CDMO services. This includes producing various batches of the drug candidate, including Process Performance Qualification - PPQ batches, in preparation for regulatory approval and future launch.
Tuesday, LFCR rose 2.10% to close at $6.81 and slipped 1.76% after hours to end at $6.69 on the NasdaqGS.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Lifecore Biomedicalmehr Nachrichten
Analysen zu Lifecore Biomedicalmehr Analysen
Aktien in diesem Artikel
Lifecore Biomedical | 6,10 | -0,81% |
|